Trial Profile

Randomized, Controlled, Double-Masked Study to Evaluate the Efficacy of IRX-101 in Reducing Post-Intravitreal Injection Pain and Corneal Epitheliopathy

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 15 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IRX-101 (Primary) ; Povidone iodine
Indications Corneal disorders; Ocular pain
Focus Adverse reactions; Registrational
Acronyms RELIEF
Sponsors iRenix Medical

Most Recent Events

09 Jun 2023 Phase of the trial is changed form phase 3 to phase 2. Primary efficacy end-point "Patient-reported post-injection pain scores" is replaced by primary safety end-point- "Safety of new drug", thus changing trial focus from "TU" to "AR". Planned patient number is decreased.
09 Jun 2023 Planned number of patients changed from 240 to 75.
02 Mar 2023 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com